# Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

> **NCT06918782** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The University of Hong Kong** · enrollment: 47 (estimated)

## Conditions studied

- Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Osimertinib plus platinum doublet chemotherapy

## Key facts

- **NCT ID:** NCT06918782
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06918782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06918782, "Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06918782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*